Leslie Gautam

Leslie Gautam is a Director in Stifel’s Global Healthcare Group with more than 15 years of experience advising biopharma companies on a broad range of strategic decisions as both a member of the Corporate Management Team and as a financial advisor. With extensive biopharma strategic advisory experience, Leslie has worked on transactions in clinical and commercial stage companies with a particular focus in specialty therapeutic categories such as CNS, Ophthalmology and Women’s Health. Leslie became part of Stifel in 2023 through the Torreya acquisition.

Prior to joining Torreya, Leslie was a senior member of the healthcare practice at Houlihan Lokey where she provided strategic advice on a variety of biopharma transactions, including: M&A, restructurings, independent Board advice, and capital raising. Leslie was a member of the Business Development teams at both Purdue Pharma and Noven Pharmaceuticals. Before working within the biopharmaceutical industry, she was an institutional investor ranked equity research analyst for UBS covering the pharmaceutical sector, including Pfizer, Eli Lilly, Allergan, Valeant, Endo, Teva, and Mylan. She began her career in the healthcare investment banking group of BMO Capital Markets, where she worked on a wide range of transactions, including sell side and buy side M&A transactions and debt and equity financings.

Leslie holds a B.S. in Psychobiology and Computer Programming from UCLA and an M.B.A. in Finance from Columbia Business School.